Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population—12-Month Clinical Outcome

Table 1

Study patient characteristics.

	Magmaris patients N-193	Ultimaster patients N-169	value
Age	66.3 ± 8.9	65.2 ± 9.34	0.605
Gender-male (ratio)	150 (77.7%)	128 (75.7%)	0.481
Unstable angina	30 (15.5%)	81 (47.9%)	<0.001
NSTEMI	163 (84.5%)	88 (52.1%)	<0.001
Diabetes mellitus type 2	72 (37.3%)	59 (34.9%)	0.789
Oral antidiabetic treatment	58 (30%)	45 (26.6%)	0.724
Insulin	14 (7.2%)	14 (8.2%)	0.844
Hypertension	171 (88.6%)	158 (93.5%)	0.143
Hyperlipidemia	152 (78.7%)	130 (76.9%)	0.812
Atrial fibrillation	9 (4.6%)	24 (14.2%)	0.002
Previous PCI	78 (40.4%)	61 (36.1%)	0.443
Primary diagnosis of MI	59 (30.5%)	60 (35.5%)	0.499
LV-EF	60.4% ± 10.9	53.6% ± 13.1	<0.001
Total cholesterol (mmol/L)	4.6 ± 1.3	4.95 ± 1.4	0.041
LDL (mmol/L)	2.5 ± 1.2	2.92 ± 1.9	0.025
Triglycerides (mmol/L)	1.8 ± 1.8	1.6 ± 0.8	0.181
Creatinine (µmol/l)	84.1 ± 22.2	82.9 ± 21.9	0.767
Days of hospitalization	2.7 ± 1.8	3.9 ± 2.9	0.041

Abbreviations: NSTEMI, non-ST elevation myocardial infarction; TIA, transient ischemic attack; PCI, percutaneous coronary intervention; LV-EF, left ventricular ejection fraction; MI, myocardial infarction.